About Us

Hubei halfsky pharmaceutical consists of Hainan halfsky pharmaceutical company, Wuhan halfsky pharmaceutical company, Wuhan halfsky technology company and Hubei halfsky pharmaceutical company. It is a biomedical high-tech enterprise focusing on the research and development, production and sales of anti-tumor, pediatric medicine, parenteral nutrition support preparations and raw materials.

The company's research and development center is located in Wuhan East Lake High-tech Optical Valley Biological City, the existing research and development personnel of 50 people, including 10 doctors, master 15 people. R & D center existing area of 7000 square meters. Invested 0.15 billion yuan successively for the purchase of research and development equipment and instruments.

The company has introduced a Chinese-American professor from the "National Thousand-Person Plan" of the Central Organization Department as the chief scientist. Established an "Academician Workstation" with China Pharmaceutical University. In December 2018, it won 4 special projects of "Major New Drug Creation" by the State Ministry of Science and Technology and the Health Commission. Among them, the innovative drug compound amino acid injection 18AA-V-SF, 14AA-SF varieties, and the standard drafting research unit of Chinese Pharmacopoeia, in January 2020 and March 2021, respectively, it was included in the national negotiated medical insurance drug list, and the company was approved by the State Administration of Drug Administration in January 2021 as the "Key Laboratory of Preparation Quality Research and Control".

The company has successively obtained the provincial "Enterprise Technology Center", "Provincial Cancer Nutrition Drug Engineering Research Center", "Provincial Intellectual Property Demonstration Enterprise", "High-tech Enterprise" of the Ministry of Science and Technology, Provincial "High-value Intellectual Property Cultivation Enterprise", and "Intellectual Property Application Demonstration Enterprise" certificate. In 2016, "Research on Key Technologies of Gemcitabine Hydrochloride and Preparations" won the second prize of "Science and Technology Progress Award" of the provincial government ". In 2018, it won the title of "National Advanced Private Enterprise for Employment and Social Security" and "Double Innovation Strategy Team" of the Provincial Science and Technology Department. In 2019, it was rated as "invisible champion in the subdivision of pillar industries in the province" and "intelligent manufacturing demonstration enterprise" by the Provincial Department of Industry and Information Technology ".

During the epidemic, the company actively donated drugs to some hospitals across the country and donated materials to charitable units and medical institutions in the province, with a cumulative amount of more than 10 million yuan.